After Horizon Pharma announced that it has submitted a biologics license application, or BLA, to the FDA for teprotumumab for the treatment of active thyroid eye disease, Stifel analyst Annabel Samimy noted that priority review was requested and she said it is likely to be granted. A six-month review following a 60-day acceptance period could put teprotumumab on the market by the first half of 2020, said Samimy, who believes the company's transition to actively position themselves ahead of the teprotumumab launch has not yet been appropriately reflected in the shares. She reiterates a Buy rating and $35 price target on Horizon.